FDA Grants Priority Review to Garetosmab for Ultra-Rare Bone Disease Fibrodysplasia Ossificans Progressiva
核心洞察
The FDA has accepted Regeneron's biologics license application for garetosmab under Priority Review, with a target decision date of August 2026 for treating adults with fibrodysplasia ossificans progressiva (搜索) (FOP (搜索)).
Phase 3 OPTIMA trial results showed garetosmab achieved 94% and 90% reductions in new heterotopic ossification (搜索) lesions at 3 mg/kg and 10 mg/kg doses respectively, compared to placebo.
If approved, garetosmab would become the first and only available treatment for FOP (搜索), an ultra-rare genetic disorder affecting approximately 900 people worldwide.
The U.S. Food and Drug Administration has accepted Regeneron Pharmaceuticals' biologics license application for garetosmab under Priority Review for the treatment of adults with fibrodysplasia ossificans progressiva (搜索) (FOP (搜索)), setting a target decision date of August 2026. If approved, garetosmab would represent the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with this devastating ultra-rare genetic disorder.
Breakthrough Results from Phase 3 Trial
The application is supported by efficacy and safety data from the positive Phase 3 OPTIMA trial, which enrolled 63 participants aged 18 years and older with active FOP (搜索). The study evaluated two doses of garetosmab (3 mg/kg and 10 mg/kg) administered intravenously once every four weeks for 56 weeks, compared to placebo.
Both garetosmab doses demonstrated remarkable efficacy in reducing new heterotopic ossification (搜索) (HO) lesions. Patients receiving the 3 mg/kg dose experienced a 94% reduction in the total number of new HO lesions compared to placebo (1 lesion vs. 19 lesions; p=0.0274), while those receiving the 10 mg/kg dose achieved a 90% reduction (2 lesions vs. 19 lesions; p=0.0260).
A post-hoc analysis revealed even more striking results for lesion volume. Both doses of garetosmab demonstrated a greater than 99% reduction in mean total volume of new HO lesions compared to placebo. The 3 mg/kg dose reduced volume to 0.01 cm³ versus 10.45 cm³ for placebo (nominal p=0.0013), while the 10 mg/kg dose achieved 0.02 cm³ versus 10.45 cm³ for placebo (nominal p=0.0005).
Safety Profile and Regulatory Pathway
At 56 weeks, serious treatment-emergent adverse events occurred in one patient treated with 3 mg/kg garetosmab, two patients treated with 10 mg/kg garetosmab, and two patients treated with placebo. The most common adverse reactions with an incidence of 30% or greater included epistaxis, increased hair growth, abscess, and acne.
The FDA has previously granted garetosmab Fast Track designation and Orphan Drug Designation for the prevention of HO in patients with FOP (搜索). The drug has also received Orphan Designation in the European Union, with additional regulatory submissions planned worldwide.
Addressing Critical Unmet Medical Need
FOP (搜索) is a relentless, ultra-rare genetic disorder characterized by the progressive infiltration of muscles, tendons, ligaments, and other connective tissues by abnormal bone formation. This process, known as heterotopic ossification (搜索), results in significant dysfunction and skeletal deformity. HO affecting the jaw, spine, hip, and rib cage can severely impair speaking, eating, walking, and breathing, leading to weight loss and escalating loss of mobility.
The disease progression is devastating, with most people with FOP (搜索) becoming wheelchair-bound by age 30. The median age of survival is approximately 56 years. Approximately 900 people are diagnosed with FOP worldwide, though many others are thought to remain undiagnosed or misdiagnosed.
Novel Mechanism of Action
Garetosmab represents a targeted approach to FOP (搜索) treatment. The fully-human monoclonal antibody, developed using Regeneron's VelocImmune technology, binds and neutralizes Activin A, a protein that Regeneron scientists discovered plays a key role in FOP by driving heterotopic ossification (搜索).
The OPTIMA trial enrolled participants who had any FOP (搜索)-causing variant of type I Activin A receptor (ACVR1 (搜索)), exhibited FOP disease activity or progression of HO lesions, and had a cumulative analogue joint involvement scale (CAJIS) score of 19 or higher at screening. CAJIS is a clinician-assessed tool with higher scores representing greater disease severity on a scale of 0 to 30.
Expanding Clinical Development
A Phase 3 trial of garetosmab in adolescents and children with FOP (搜索), called OPTIMA 2, is planned to begin later this year. This expansion reflects the urgent need for treatment options across all age groups affected by this progressive disorder.
Priority Review designation is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis, or prevention of serious conditions, underscoring the FDA's recognition of garetosmab's potential to address this critical unmet medical need.